Introduction
Tuberous sclerosis complex (TSC) is a genetic disease often with in utero onset, which is characterized by benign tumors affecting multiple organs including the heart, central nervous system, skin, kidney, and lungs. [1] [2] [3] The broad range of clinical guidelines with the aim of streamlining the diagnostic and therapeutic approach of TSC-related organ manifestations.
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The discovery of mutations in the TSC1 and TSC2 genes 9,10 and their association with the mechanistic target of rapamycin (mTOR) pathway was the basis for the development of a targeted therapy in TSC patients. 11 A large number of randomized controlled clinical trials with mTOR inhibitors have shown efficacy in the treatment of several clinical organ manifestations of TSC, most importantly in patients with subependymal giant cell astrocytoma (SEGA), seizures (treatment-resistant with focal-onset), and angiomyolipoma (AML), as well as cutaneous manifestations.
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The main objectives of this study were to characterize two samples of TSC patients who attended two different university hospitals (Barcelona, Spain, and Homburg, Germany) with regard to the clinical manifestations of TSC and to assess the quality of the diagnostic and therapeutic approach with regard to published recommendations for diagnosis and surveillance of TSC patients.
Patients and Methods
This is a retrospective, multicenter study of TSC patients seen at the Pediatric Neurology Service of Vall d'Hebron University Hospital (HVH), Barcelona, Spain (January 1982 to May 2015), and the Department of Pediatric Neurology at Saarland University Medical Center (UKS), Homburg, Germany (May 1998 to May 2015).
Patients with a possible or definitive diagnosis of TSC based on available current diagnostic criteria at the time were included. 4, 5, 7 Patients with insufficient data documentation were excluded. All patient files, both handwritten and electronic charts, were reviewed to assess all TSC relevant clinical manifestations, the initial diagnostic approach, and further surveillance management, and whether they were done in line with available current clinical guidelines and recommendations at the time. Results from genetic testing as well as therapy with mTOR inhibitor were included in this study as available. For both cohorts, we assumed that a specific organ manifestation was inappropriately assessed if more than 15% of the patients did not receive adequate clinical management with regard to specific organ manifestation (diagnosis and follow-up). Furthermore, we compared these data between two study periods (prior to and after 2006).
For patients treated with mTOR inhibitors, both treatment duration and response were assessed. If available, results from genetic testing for mutations in the TSC1 or TSC2 gene was also included into our data analysis.
All data were analyzed with IBM-SPSS Version 22 (SPSS Inc., Chicago, Illinois, United States) using nonparametric tests (qualitative variables with chi-square test, and quantitative variables with Mann-Whitney U test). Data are presented as mean, median, standard deviation, interquartile range, and range as appropriate. Statistical significance was assigned if p-value was <0.05.
Results

General Demographics
Initially, 58 patients were identified, 4 of whom were excluded because of inappropriate medical records or not meeting diagnostic criteria for TSC. A definite diagnosis was made in 52 (96%) patients and a possible diagnosis was made in 2 (4%) patients ( The median age at first presentation was 6 months (interquartile range: 0-38 months), and the median time of follow-up was 6 years (interquartile range: 2-13 years) (►Supplementary Fig. S1 ). There was no statistical difference in terms of patient distributions and prevalence of symptoms between the two hospitals.
Results of molecular analysis were available in 31/54 (57%) patients: 23/31 (74%) patients demonstrated mutations in the TSC2 gene, 5/31 (16%) patients demonstrated mutations in TSC1 gene, and 3/31 (10%) patients were without TSC1/TSC2 gene mutation. mTOR inhibitors were given to 12/54 (22%) patients (11 everolimus, 1 sirolimus) at an average age of 10 years (standard deviation: 6.9; range 0-24). Patients were treated on average for 28 months (range: 6-50 months).
TSC Nonneurologic Manifestations, Treatment, and Response
►Figs. 1 and 2 summarize the main clinical symptoms.
The most frequent manifestation that led to a diagnosis of TSC was the presence of cardiac rhabdomyoma (22/54 [41%] patients, 16 of whom were diagnosed by prenatal ultrasound). Overall, cardiac rhabdomyomas were diagnosed in 38/54 (70%) patients. In 9/38 (24%) patients, involution of rhabdomyomas was noted during follow-up visits. Cardiac arrhythmias were seen in 3/54 (6%) patients.
The existence of renal AML was diagnosed in 30/54 (56%) patients with a median age of 9 years (interquartile range 6-10 years), and in 3 of them, the following treatment was given: nephrectomy in 1, embolization in 1, and mTOR inhibitor (sirolimus) in 1. The patient who received sirolimus experienced a reduction of renal AML size.
Liver AML were seen in seven patients. Retinal hamartomas were seen in 14 patients at a median age of 3 years (interquartile range: 0-8 years).
The cutaneous manifestations were as follows: white spots (35 patients), facial angiofibroma (26 patients), shagreen patch (12 patients), fibrous cephalic plaque (9 patients), gingival fibroma (6 patients), ungual fibroma (4 patients), and dental pits (1 patient). A statistically significant association was found between TSC2 mutations and the occurrence of facial angiofibromas (p ¼ 0.001), fibrous cephalic plaque (p ¼ 0.008), and shagreen patch (p ¼ 0.014).
Epilepsy Manifestations and Treatment
Epilepsy was the second most common manifestation that led to a diagnosis of TSC (20/54 [37%] patients). During the follow-up period, a total of 38/54 (70%) patients had epilepsy. The average age at first onset of seizures was less than one 1 year (interquartile range: 0-1 years). Infantile spasms were seen in 14/38 (37%) patients and focal seizures in 24/38 (63%) patients. Patients were treated with 3 AEDs on average (median: 3; range: 0-12). Refractory epilepsy was diagnosed in 20/38 (53%) patients. ►Fig. 3 depicts the use of AEDs depending on hospital location. ►Fig. 4 shows which AED medications were given to those patients who achieved good seizure control ( In 47/54 (87%) patients, brain imaging abnormalities were found (►Fig. 2). SEGA was diagnosed in 18/54 (33%) patients. Everolimus was used in 10 patients with SEGA (6 UKS, 4 HVH), and at UKS, 2 patients underwent endoscopic SEGA resection (at 6 and 12 years of age). One patient developed blindness due to severe bilateral papilledema secondary to SEGA growth. The SEGA response was as follows: reduction in SEGA size in 5 patients, unchanged SEGA in four patients, and in SEGA growth was noted in 1 patient.
Neurodevelopmental Findings
In 28/54 (52%) patients, a diagnosis of developmental delay was made. Developmental delay was statistically associated with a diagnosis of SEGA and epilepsy (p ¼ 0.001 and 0.043, respectively). A formal intelligence test was performed in five patients (range: 32-103). Neuropsychiatric disorders were diagnosed in 8/54 (15%) patients (5 with autism). No significant differences were seen with regard to age between patients with and without neuropsychiatric pathologies.
►Fig. 5 and ►Supplementary Table S1 summarize the examinations performed in our cohort. In summary, the following examinations were insufficiently performed and/ or documented: neuropsychiatric evaluation in 41/54 (76%) patients, renal imaging studies (ultrasound/MRI) in 11/54 (20%) patients, ophthalmological examination in 15/54 patients (28%), and dermatological examination in 11/54 (20%) patients. Similar results were found between the study periods (►Supplementary Table S2 ) as well as between both hospitals, except for inadequate dermatological assessment, which was only seen at UKS (p ¼ 0.006). 
Discussion
In our study, all patients fulfilled the current diagnostic criteria for TSC or possible TSC. Due to the retrospective nature of our study, it was only possible to assess whether TSC1 or TSC2 mutations existed with regard to their pathogenicity, thus contributing to establishing a diagnosis of TSC in all affected patients. Of note, in all but two patients, a diagnosis of TSC could be established using clinical criteria only.
No differences were found in terms of patients' demographics between both hospitals. To assess if patients underwent an appropriate diagnostic work-up of the TSC-related manifestations, the published recommendations from 1999 as well as from 2013 were used. 6, 8 Contrary to previous reports, the first key symptom that led to the diagnosis of TSC in our cohort was, for both hospitals, the detection of cardiac rhabdomyoma, most often in utero, followed by epilepsy. 20, 21 Compared with previous reports, a higher rate of in utero detection of cardiac rhabdomyoma was seen in our two cohorts, indicating improved antenatal care. 22 We found a lower percentage of patients with epileptic spasms (26%) compared with other clinical studies (33-54%) as well as higher percentage of patients with refractory epilepsy (54%) compared with previous reports (34-44%). [23] [24] [25] [26] [27] This may be because of the use of different definitions of refractory epilepsy. 18 According to other studies, valproate and vigabatrin are the most common AEDs used in TSC. 28 Differences in the use of sulthiame between our two cohorts can be easily explained by a lack of availability of sulthiame in Spain.
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In this study, we found a higher prevalence of SEGA compared with other series. 17, 23, 25, [30] [31] [32] [33] This may also be because of differences in SEGA definitions and improvement of cerebral imaging studies, most importantly the widespread use of high-resolution MRI. We found a similar response rate of SEGA to everolimus as in previous reports.
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Of note, two patients underwent a neurosurgery procedure, both treated at UKS. This may have to do with differential experiences in the surgical treatment of TSC patients with SEGA. 31, 35 The percentage of patients with developmental delay was similar when compared with previous reports. 23, 25, 33 As described previously, a positive correlation between epilepsy and neurodevelopmental delay could be established; however, and contrary to other reports, we also found an association between neurodevelopmental delay and SEGA. 26, 36 Possibly, this association may be indicative of the extent of further underlying CNS pathology, for example, the number of cortical tubers. Unfortunately, due to the retrospective nature of our study, it was not possible to quantify in full detail all CNS pathologies, including the number, size, and location of cortical tubers in our study cohorts. Of note, this is the first multicenter and international comparison (Spain, Germany) that demonstrates that TSC patients were often not managed in accordance with the current guidelines for diagnosis and long-term treatment. This effect was most apparent with regard to inappropriate assessment of neuropsychiatric, renal, ophthalmological and dermatological manifestations. This pattern was found in both hospitals (HVH and UKS), except for inadequate skin examination, which was only seen at UKS. Of importance, a specific screening test for TSC-associated neuropsychiatric disorders has been published after data completion, thus potentially improving this shortcoming. 37 We found a higher prevalence of renal AML compared with previous reports. This finding could be explained by neither population demographics nor different prevalence of TSC2 mutations, 21,38 but may at least in part be also attributed to the use of more sophisticated and readily available imaging modalities (ultrasound). Conversely, a possible explanation for the inappropriate use and implementation of renal examinations may be the young age of our two cohorts: in clinical practice, renal ultrasound is first performed at school age since the occurrence of clinically relevant renal 5 Examinations performed in the study cohort. Brain, brain imaging; Card., cardiological examination; Derm., dermatological examination; Dev., neurodevelopmental evaluation; Kidney, renal ultrasound; Opht., ophthalmological examination; Psych., neuropsychiatric evaluation.
angiomyolipoma is usually seen at a later age (school age and thereafter). Undoubtedly, this study has several weaknesses. First, this is a retrospective analysis with all its inherent shortcomings. Second, given the rarity of this disease, the number of patients included is limited. Third, the inclusion period spans almost four decades with substantial changes in both diagnostic and therapeutic approaches over time. Moreover, as a reference for adequate patient management of TSC patients, we used the definition of Roach et al from 1999, and current surveillance and management recommendations (Krueger and Northrup) were only used in patients included after 2013. 6, 8 Fourth, the cutoff value for inadequate management of TSC patients was somewhat arbitrarily chosen at >15%. In summary, this is the first multicenter and international study (Spain, Germany), which demonstrates that TSC patients were often not managed in accordance with current guidelines on diagnosis and long-term treatment. This effect was most relevant with regard to inappropriate assessment of neuropsychiatric, renal, ophthalmological and cutaneous manifestations. More widespread application/use of current guidelines on diagnosis and long-term management has the potential to improve the care of TSC patients.
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